APO Research
Talk to an analyst

APO RESEARCH · REPORT

Japanese Encephalitis Inactivated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Japanese Encephalitis Inactivated Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025195 pages

Choose your research edition.

Industry ResearchJapanese Encephalitis Inactivated Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Japanese Encephalitis Inactivated Vaccine Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Japanese Encephalitis Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Japanese Encephalitis Inactivated Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Japanese Encephalitis Inactivated Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Japanese Encephalitis Inactivated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Japanese Encephalitis Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Japanese Encephalitis Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Japanese Encephalitis Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Japanese Encephalitis Inactivated Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Japanese Encephalitis Inactivated Vaccine market include Liaoning Chengda Biological Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Chengdu Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co., Ltd, Valneva, Sanofi Pasteur and Biken, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Japanese Encephalitis Inactivated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Japanese Encephalitis Inactivated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Japanese Encephalitis Inactivated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Japanese Encephalitis Inactivated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Japanese Encephalitis Inactivated Vaccine Segment by Company

Liaoning Chengda Biological Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Chengdu Institute of Biological Products Co., Ltd

Beijing Institute of Biological Products Co., Ltd

Valneva

Sanofi Pasteur

Biken

Japanese Encephalitis Inactivated Vaccine Segment by Type

Adult

Child

Japanese Encephalitis Inactivated Vaccine Segment by Application

Hospital

Clinic

Japanese Encephalitis Inactivated Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Japanese Encephalitis Inactivated Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Japanese Encephalitis Inactivated Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Japanese Encephalitis Inactivated Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Japanese Encephalitis Inactivated Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Japanese Encephalitis Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Japanese Encephalitis Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Japanese Encephalitis Inactivated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Japanese Encephalitis Inactivated Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Japanese Encephalitis Inactivated Vaccine industry.

Chapter 3: Detailed analysis of Japanese Encephalitis Inactivated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Japanese Encephalitis Inactivated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Japanese Encephalitis Inactivated Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Japanese Encephalitis Inactivated Vaccine Industry Trends Table 2. Japanese Encephalitis Inactivated Vaccine Industry Drivers Table 3. Japanese Encephalitis Inactivated Vaccine Industry Opportunities and Challenges Table 4. Japanese Encephalitis Inactivated Vaccine Industry Restraints Table 5. Global Japanese Encephalitis Inactivated Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Japanese Encephalitis Inactivated Vaccine Revenue Share by Company (2021-2026) Table 7. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Japanese Encephalitis Inactivated Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Japanese Encephalitis Inactivated Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Japanese Encephalitis Inactivated Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Japanese Encephalitis Inactivated Vaccine Company, Product Type & Application Table 13. Global Japanese Encephalitis Inactivated Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Japanese Encephalitis Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adult Table 18. Significant Companies of Child Table 19. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Japanese Encephalitis Inactivated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Japanese Encephalitis Inactivated Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Japanese Encephalitis Inactivated Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Japanese Encephalitis Inactivated Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Japanese Encephalitis Inactivated Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Japanese Encephalitis Inactivated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Japanese Encephalitis Inactivated Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Japanese Encephalitis Inactivated Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Japanese Encephalitis Inactivated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Japanese Encephalitis Inactivated Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Japanese Encephalitis Inactivated Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Japanese Encephalitis Inactivated Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Japanese Encephalitis Inactivated Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Japanese Encephalitis Inactivated Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Japanese Encephalitis Inactivated Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Liaoning Chengda Biological Co., Ltd Company Information Table 64. Liaoning Chengda Biological Co., Ltd Business Overview Table 65. Liaoning Chengda Biological Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Liaoning Chengda Biological Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 67. Liaoning Chengda Biological Co., Ltd Recent Development Table 68. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 69. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 70. Lanzhou Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Lanzhou Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 72. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 73. Chengdu Institute of Biological Products Co., Ltd Company Information Table 74. Chengdu Institute of Biological Products Co., Ltd Business Overview Table 75. Chengdu Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chengdu Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 77. Chengdu Institute of Biological Products Co., Ltd Recent Development Table 78. Beijing Institute of Biological Products Co., Ltd Company Information Table 79. Beijing Institute of Biological Products Co., Ltd Business Overview Table 80. Beijing Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Beijing Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 82. Beijing Institute of Biological Products Co., Ltd Recent Development Table 83. Valneva Company Information Table 84. Valneva Business Overview Table 85. Valneva Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Valneva Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 87. Valneva Recent Development Table 88. Sanofi Pasteur Company Information Table 89. Sanofi Pasteur Business Overview Table 90. Sanofi Pasteur Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sanofi Pasteur Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 92. Sanofi Pasteur Recent Development Table 93. Biken Company Information Table 94. Biken Business Overview Table 95. Biken Japanese Encephalitis Inactivated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Biken Japanese Encephalitis Inactivated Vaccine Product Portfolio Table 97. Biken Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Japanese Encephalitis Inactivated Vaccine Distributors List Table 101. Japanese Encephalitis Inactivated Vaccine Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Japanese Encephalitis Inactivated Vaccine Product Image Figure 2. Global Japanese Encephalitis Inactivated Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Japanese Encephalitis Inactivated Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Japanese Encephalitis Inactivated Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Japanese Encephalitis Inactivated Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adult Image Figure 10. Child Image Figure 11. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Japanese Encephalitis Inactivated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Japanese Encephalitis Inactivated Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Japanese Encephalitis Inactivated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Japanese Encephalitis Inactivated Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Japanese Encephalitis Inactivated Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Adult
  • Child
Applications
  • Hospital
  • Clinic
Companies covered
  • Liaoning Chengda Biological Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Chengdu Institute of Biological Products Co., Ltd
  • Beijing Institute of Biological Products Co., Ltd
  • Valneva
  • Sanofi Pasteur
  • Biken

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Japanese Encephalitis Inactivated Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Japanese Encephalitis Inactivated Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Japanese Encephalitis Inactivated Vaccine Market Dynamics
  1. 2.1 Japanese Encephalitis Inactivated Vaccine Industry Trends
  2. 2.2 Japanese Encephalitis Inactivated Vaccine Industry Drivers
  3. 2.3 Japanese Encephalitis Inactivated Vaccine Industry Opportunities and Challenges
  4. 2.4 Japanese Encephalitis Inactivated Vaccine Industry Restraints
3 Japanese Encephalitis Inactivated Vaccine Market by Company
  1. 3.1 Global Japanese Encephalitis Inactivated Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Japanese Encephalitis Inactivated Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Japanese Encephalitis Inactivated Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Japanese Encephalitis Inactivated Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Japanese Encephalitis Inactivated Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Japanese Encephalitis Inactivated Vaccine Company Product Type and Application
  8. 3.8 Global Japanese Encephalitis Inactivated Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Japanese Encephalitis Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Japanese Encephalitis Inactivated Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Japanese Encephalitis Inactivated Vaccine Market by Type
  1. 4.1 Japanese Encephalitis Inactivated Vaccine Type Introduction
  2. 4.1.1 Adult
  3. 4.1.2 Child
  4. 4.2 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type
  5. 4.2.1 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type
  9. 4.3.1 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type (2021-2032)
5 Japanese Encephalitis Inactivated Vaccine Market by Application
  1. 5.1 Japanese Encephalitis Inactivated Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application
  5. 5.2.1 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Japanese Encephalitis Inactivated Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Japanese Encephalitis Inactivated Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application
  9. 5.3.1 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application (2021-2032)
6 Japanese Encephalitis Inactivated Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Japanese Encephalitis Inactivated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Japanese Encephalitis Inactivated Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Japanese Encephalitis Inactivated Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Japanese Encephalitis Inactivated Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Japanese Encephalitis Inactivated Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Japanese Encephalitis Inactivated Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Japanese Encephalitis Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
7 Japanese Encephalitis Inactivated Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Japanese Encephalitis Inactivated Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Japanese Encephalitis Inactivated Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Japanese Encephalitis Inactivated Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Japanese Encephalitis Inactivated Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Japanese Encephalitis Inactivated Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Japanese Encephalitis Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Liaoning Chengda Biological Co., Ltd
  2. 8.1.1 Liaoning Chengda Biological Co., Ltd Company Information
  3. 8.1.2 Liaoning Chengda Biological Co., Ltd Business Overview
  4. 8.1.3 Liaoning Chengda Biological Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Liaoning Chengda Biological Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio
  6. 8.1.5 Liaoning Chengda Biological Co., Ltd Recent Developments
  7. 8.2 Lanzhou Institute of Biological Products Co., Ltd
  8. 8.2.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  9. 8.2.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  10. 8.2.3 Lanzhou Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Lanzhou Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio
  12. 8.2.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  13. 8.3 Chengdu Institute of Biological Products Co., Ltd
  14. 8.3.1 Chengdu Institute of Biological Products Co., Ltd Company Information
  15. 8.3.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
  16. 8.3.3 Chengdu Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Chengdu Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio
  18. 8.3.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
  19. 8.4 Beijing Institute of Biological Products Co., Ltd
  20. 8.4.1 Beijing Institute of Biological Products Co., Ltd Company Information
  21. 8.4.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  22. 8.4.3 Beijing Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Beijing Institute of Biological Products Co., Ltd Japanese Encephalitis Inactivated Vaccine Product Portfolio
  24. 8.4.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  25. 8.5 Valneva
  26. 8.5.1 Valneva Company Information
  27. 8.5.2 Valneva Business Overview
  28. 8.5.3 Valneva Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Valneva Japanese Encephalitis Inactivated Vaccine Product Portfolio
  30. 8.5.5 Valneva Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Japanese Encephalitis Inactivated Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Biken
  38. 8.7.1 Biken Company Information
  39. 8.7.2 Biken Business Overview
  40. 8.7.3 Biken Japanese Encephalitis Inactivated Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biken Japanese Encephalitis Inactivated Vaccine Product Portfolio
  42. 8.7.5 Biken Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Japanese Encephalitis Inactivated Vaccine Value Chain Analysis
  2. 9.1.1 Japanese Encephalitis Inactivated Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Japanese Encephalitis Inactivated Vaccine Sales Mode & Process
  6. 9.2 Japanese Encephalitis Inactivated Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Japanese Encephalitis Inactivated Vaccine Distributors
  9. 9.2.3 Japanese Encephalitis Inactivated Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst